Flexion Therapeutics

Flexion Therapeutics is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis, a type of degenerative arthritis. The Company's lead product candidate, Zilretta™ (FX006), is an extended release intra-articular, analgesic candidate in late-stage development for moderate to severe osteoarthritis pain.

Zilretta™ has received Fast Track Designation from the FDA. This designation is given to a drug in clinical development that is intended to treat a serious condition and addresses unmet medical need.

Company Growth (employees)
Type
Public
HQ
Burlington, US
Founded
2007
Size (employees)
95 (est)+98%
Flexion Therapeutics was founded in 2007 and is headquartered in Burlington, US

Key People/Management at Flexion Therapeutics

Mike Clayman

Mike Clayman

Chief Executive Officer & Co-Founder
Neil Bodick

Neil Bodick

Chief Medical Officer & Co-Founder

Flexion Therapeutics Office Locations

Flexion Therapeutics has an office in Burlington
Burlington, US (HQ)
301 10 Burlington Mall Road

Flexion Therapeutics Financials and Metrics

Flexion Therapeutics Financials

USD

Net income (Q2, 2017)

(28.9 m)

EBIT (Q2, 2017)

(26.9 m)

Market capitalization (13-Nov-2017)

749.7 m

Cash (30-Jun-2017)

197.2 m

EV

562.5 m
Flexion Therapeutics's current market capitalization is $749.7 m.
USDFY, 2014FY, 2015FY, 2016

R&D expense

17.9 m32.7 m41.3 m

General and administrative expense

9.1 m13.4 m28.5 m

Operating expense total

27 m46.1 m69.8 m

EBIT

(27 m)(46.1 m)(69.8 m)
USDQ1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

R&D expense

6.3 m9.6 m7.8 m12 m8.9 m9 m10.8 m11.8 m

General and administrative expense

2.8 m2.9 m3.2 m4.7 m5.2 m8.4 m13 m15.1 m

Operating expense total

9 m12.5 m11 m16.7 m14.1 m17.4 m23.8 m26.9 m

EBIT

(9 m)(12.5 m)(11 m)(16.7 m)(14.1 m)(17.4 m)(23.8 m)(26.9 m)
USDFY, 2014FY, 2015FY, 2016

Cash

103.1 m62.9 m30.9 m

Accounts Receivable

95.3 k55.8 m

Inventories

502.3 k760.9 k3.8 m

Current Assets

152.1 m112.1 m209.4 m
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Cash

35.8 m28.3 m73.5 m58.9 m119 m66.8 m42.9 m197.2 m

Accounts Receivable

199.6 k46.4 k56 k101 k95 k

Current Assets

79.4 m128.8 m133 m99.6 m164.5 m161.1 m190.1 m362.2 m

PP&E

392.8 k2.9 m4.2 m9.1 m11.3 m11.2 m11.8 m11.9 m
USDFY, 2014FY, 2015FY, 2016

Net Income

(27.3 m)(46.3 m)(71.9 m)

Depreciation and Amortization

120.3 k238.2 k1.2 m

Accounts Receivable

95.3 k

Inventories

(9.1 m)46.9 m(34 m)
USDQ1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017

Net Income

(6.5 m)(9.2 m)(21.6 m)(11.1 m)(16.8 m)(14.2 m)(17.8 m)(23.9 m)(52.8 m)

Depreciation and Amortization

27.3 k39.7 k82.4 k927 k

Accounts Receivable

(403.2 k)(199.6 k)46.4 k56 k101 k95 k(6 k)

Accounts Payable

671.8 k592.8 k(196.2 k)1.9 m3.1 m3.5 m2 m2.2 m736 k
Y, 2017

EV/EBIT

-20.9 x

EV/CFO

-13.3 x

Financial Leverage

1.8 x
Show all financial metrics

Flexion Therapeutics Market Value History

Flexion Therapeutics's Web-traffic and Trends

Flexion Therapeutics Online and Social Media Presence

Flexion Therapeutics Company Life and Culture

You may also be interested in